计算溶液所需的质量、体积或浓度。
活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
---|
货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
---|---|---|---|---|
B409219-1ml |
1ml |
现货 ![]() |
|
英文别名 | 1H-Indol-5-ol, 3-(1-methyl-4-piperidinyl)- |
---|---|
规格或纯度 | Moligand™, 10mM in DMSO |
英文名称 | BRL-54443 |
生化机理 | BRL 54443 是一种 5-HT1E 和 5-HT1F 受体激动剂,pKi分别为 8.7 和 9.25,与 5-HT1A、5-HT1B、5-HT1D 受体的结合亲和力较弱。 |
储存温度 | -80℃储存 |
运输条件 | 超低温冰袋运输 |
作用类型 | 激动剂 |
作用机制 | 5-HT 1e 受体激动剂;5-HT 1F 受体激动剂 |
产品介绍 |
BRL-54443是一种5-HT1E和5-HT1F受体激动剂,pKi分别为8.7和9.25,对5-HT1A, 5-HT1B, 5-HT1D受体具有弱的结合亲和力。A potent agonist at SR-1E and SR-1F. Information BRL 54443 is a5-HT1Eand5-HT1Freceptor agonist withpKiof 8.7 and 9.25, respectively, with a weak binding affinity for 5-HT1A, 5-HT1B, 5-HT1D receptors. BRL 54443 has also measurable affinity for the 5-HT2A receptor. BRL 54443 induces contraction with a −logEC50 of 6.52. Contraction caused by BRL 54443 is likely mediated through stimulation of 5-HT5-HT2A receptors. In vivo BRL 54443 induces an immediate dose-dependent maximal intragastric volume increase vs. saline. cell lines:Renca or 786-O cells, mouse endothelial cells and splenic CD11b+/c-myeloid cells, HUVECs Concentrations: Incubation Time: Powder Purity:≥99% |
Ki Data | 5-HT1B, pKi: 6.9; 5-HT1D, pKi: 7.2; 5-HT1A, pKi: 7.2; 5-HT1F, pKi: 9.25; 5-HT1E, pKi: 8.7 |
---|---|
ALogP | 2.572 |
HBD Count | 2 |
Rotatable Bond | 1 |
Canonical SMILES | CN1CCC(CC1)C2=C[NH]C3=C2C=C(O)C=C3 |
---|---|
分子量 | 230.31 |
Reaxy-Rn | 749183 |
Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=749183&ln= |
溶解性 | Solubility (25°C) In vitro DMSO: 38 mg/mL (204.04 mM); Ethanol: 15 mg/mL (80.54 mM); Water: Insoluble; |
---|---|
DMSO(mg / mL) Max Solubility | 46 |
DMSO(mM) Max Solubility | 199.73 |
Water(mg / mL) Max Solubility | <1 |
Reaxy-Rn | 749183 |
---|---|
Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=749183&ln= |
Concentration | 9-11(mmol/L) |
---|---|
Proton NMR spectrum | Conforms to Structure |